News
Boehringer, Lilly’s Jardiance tries to match AZ’s Farxiga wi...
Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabe
